Colorectal Cancer Rates, Mortality Down in Americans Aged ≥50

This article originally appeared here.
Share this content:
Colorectal Cancer Rates, Mortality Down in Americans Aged ≥50
Colorectal Cancer Rates, Mortality Down in Americans Aged ≥50

WEDNESDAY, March 1, 2017 (HealthDay News) -- Colorectal cancer (CRC) rates among those aged 50 and older have fallen 32 percent since 2000, while deaths from the disease fell by 34 percent, according to a report published online March 1 in CA: A Cancer Journal for Clinicians.

Among older adults, CRC rates are declining fastest in those aged 65 and older, and for tumors located in the distal colon. The decrease is slowest among those aged 50 to 64 and for rectal tumors, the authors found. For example, there was a 9 percent decline in the incidence of rectal tumors in men aged 50 to 64 and no decline among women in the same age group. But those rates dropped 38 percent in men and 41 percent in women who were over 65.

Every state saw a decrease in CRC rates among people aged 50 and older, with a decline of more than 5 percent a year seen between 2009 and 2013 in seven states: California, Delaware, Maine, Massachusetts, Nebraska, Rhode Island, and South Dakota. The slowest declines were seen in states with the highest rates of CRC: Kentucky, Louisiana, and Mississippi, according to the American Cancer Society report, which is published every three years. Following the pattern of incidence rates, CRC mortality rates decreased by 34 percent in people 50 and over during 2000 to 2014.

As screening rates went up, CRC rates declined. Between 2013 and 2015, CRC screening increased from 53 to 58 percent among those aged 50 to 64, and from 65 to 68 percent in people aged 65 and older. For both groups combined, screening rates climbed from 59 to 63 percent during those years. That increase translated into an additional 3.7 million adults aged 50 and older who were screened in 2015. If screening rates stay at that level, the authors estimated that 39,700 CRC cases and 37,200 deaths from the disease will be prevented through 2030.

One author disclosed financial ties to Ambry Genetics and EXACT Sciences and Cancer Prevention Pharmaceuticals.

Abstract
Full Text
Colorectal Cancer Facts & Figures 2017-2019

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »